Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors

PurposeThis study was designed to ascertain the dose-limiting toxicities (DLT) and maximally tolerated doses of the combination of fixed-dose tamoxifen and carboplatin, with escalating doses of topotecan, and to determine the pharmacokinetics of topotecan in the plasma and cerebrospinal fluid.MethodsTamoxifen 100 mg po bid, topotecan 0.25, 0.5, 0.75, or 1.0 mg/m2/d IV, administered as a 72 h continuous infusion on days 1–3, followed by carboplatin AUC = 3, IV on day 3. Cycles were repeated every 4 weeks.ResultsSeventeen patients received 39 cycles of treatment: median 2, (range 1–5). The tumors included glioblastoma (6), anaplastic astrocytoma (2), metastatic non-small cell (3), small cell lung (2), and one each with medulloblastoma, ependymoma, and metastatic breast or colon carcinoma. The median Karnofsky performance status was 70% (range 60–90%) and age: 52 (range 24–75). Eleven patients were female and six male. Toxicities included thrombocytopenia (2), neutropenia without fever lasting 6 days (1), DVT (2), and emesis (1). Topotecan levels, total and lactone, were measured prior to the end of infusion in plasma and cerebrospinal fluid (CSF). At 1.0 mg/m2/d, the median CSF/plasma ratio was 19.4% (range 15.1–59.1%). The total plasma topotecan in two pts with DLTs was 4.63 and 5.87 ng/ml, in three without DLTs at the same dose level the mean total plasma topotecan was 3.4 ng/ml (range 3.02–3.83). Plasma lactone levels were 33% of the total; CSF penetration was 20% of the total plasma levels. 4/8 pts with high-grade gliomas had stable disease (median: 3 cycles (range 2–5)). Two had minor responses. One patient with metastatic non-small cell and one with small cell lung cancer had objective PRs.ConclusionsThe recommended phase II doses are: tamoxifen 100 mg po bid, topotecan 0.75 mg/m2/d IV continuous infusion for 72 h, followed by carboplatin AUC = 3 IV on day 3. Measurable topotecan levels, both total and lactone, are observed in the CSF.

[1]  J. Verweij,et al.  Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine. , 1996, Journal of chromatography. B, Biomedical applications.

[2]  F. Zunino,et al.  In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems , 1998, Cancer Chemotherapy and Pharmacology.

[3]  M. Apuzzo,et al.  Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. , 1993, Neurosurgery.

[4]  L. Grochow,et al.  Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Landoni,et al.  Complete remission of brain metastases from ovarian carcinoma with carboplatin. , 1998, European journal of obstetrics, gynecology, and reproductive biology.

[6]  S. Piantadosi,et al.  Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Stephanie Green,et al.  Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.

[8]  R. Benjamin,et al.  Concentration of vinblastine in human intracerebral tumor and other tissues. , 1983, Journal of neuro-oncology.

[9]  M L Apuzzo,et al.  Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  P. Lønning,et al.  Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. , 1991, British Journal of Cancer.

[11]  P. Ueland,et al.  Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. , 1991, Cancer research.

[12]  M. Zucchetti,et al.  Do anticancer agents reach the tumor target in the human brain? , 2004, Cancer Chemotherapy and Pharmacology.

[13]  H. Grunicke,et al.  Enhancement of the antiproliferative effect of cis‐diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C , 1988, International journal of cancer.

[14]  M. Gilbert,et al.  A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. , 2008, Neuro-oncology.

[15]  W. Couldwell,et al.  Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report. , 1996, Neurosurgery.

[16]  I. Pollack,et al.  The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients. , 1992, Neurosurgery.

[17]  M. Colleoni,et al.  Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma. , 1997, American journal of clinical oncology.

[18]  H. Groen,et al.  Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. , 1993, European journal of cancer.

[19]  L. Mastronardi,et al.  Tamoxifen as a potential treatment of glioma. , 1998, Anti-cancer drugs.

[20]  M. Gilbert,et al.  The role of chemotherapy in the treatment of patients with brain metastases from solid tumors , 2009, International Journal of Clinical Oncology.

[21]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Grochow,et al.  Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. , 1996, Journal of the National Cancer Institute.

[23]  S. Rodenhuis,et al.  Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study , 2004, Cancer Chemotherapy and Pharmacology.

[24]  T. Cloughesy,et al.  Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every‐3‐week regimen , 2003, Cancer.

[25]  A. W. Boersma,et al.  Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro , 1998, Cancer Chemotherapy and Pharmacology.

[26]  A. Bernardo,et al.  First-Line Chemotherapy with Vinorelbine, Gemcitabine, and Carboplatin in the Treatment of Brain Metastases from Non-Small-Cell Lung Cancer: A Phase II Study , 2002, Cancer investigation.

[27]  F. Khuri,et al.  Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report. , 1997, Seminars in oncology.

[28]  R. McLendon,et al.  Topotecan treatment of adults with primary malignant glioma , 1999, Cancer.

[29]  C. Logothetis,et al.  The management of brain metastases in germ cell tumors , 1982, Cancer.

[30]  S. Baker,et al.  Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors , 1995, Cancer Chemotherapy and Pharmacology.

[31]  M. Larsen,et al.  Longterm remission of multiple brain metastases with tamoxifen , 1991, Journal of Neuro-Oncology.

[32]  A. Hart,et al.  Treatment and outcome of brain metastasis as first site of distant metastasis from breast cancer , 1997, Journal of Neuro-Oncology.

[33]  P. Lunardi,et al.  Tamoxifen and carboplatin combinational treatment of high-grade gliomas Results of a clinical trial on newly diagnosed patients , 1998, Journal of Neuro-Oncology.

[34]  O. Dalesio,et al.  Response of brain metastases from breast cancer to systemic chemotherapy , 1992, Cancer.

[35]  F. Balis,et al.  A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. , 1994, Cancer research.

[36]  P. Lunardi,et al.  Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study , 2005, Acta Neurochirurgica.

[37]  R. Benjamin,et al.  Concentrations of vinblastine in human intracerebral tumor and other tissues , 2004, Journal of Neuro-Oncology.

[38]  N. van Zandwijk,et al.  Teniposide Sometimes Effective in Brain Metastases from Non-small Cell Lung Cancer , 1999, Journal of Neuro-Oncology.

[39]  S. Kaufmann,et al.  Topotecan in combination chemotherapy. , 1997, Seminars in oncology.